Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for oxycodone hydrochloride sustained-release tablets was accepted. Oxycodone hydrochloride sustained-release tablets are clinically used to treat pain that is severe enough to be continued for a long time, treated with opioids on time every day, and that cannot be adequately relieved by alternative treatment. The original research drug of this product was approved for marketing in China in 2021. Currently, 2 generic drugs have been approved for listing in China, and 1 domestic company has submitted a marketing license application. Beijing Huasu is the fourth domestic company to submit a marketing license application for this generic drug. As of the disclosure date of this announcement, the oxycodone hydrochloride sustained-release tablet project has invested a total of 17.1473 million yuan in R&D expenses.

Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for oxycodone hydrochloride sustained-release tablets was accepted. Oxycodone hydrochloride sustained-release tablets are clinically used to treat pain that is severe enough to be continued for a long time, treated with opioids on time every day, and that cannot be adequately relieved by alternative treatment. The original research drug of this product was approved for marketing in China in 2021. Currently, 2 generic drugs have been approved for listing in China, and 1 domestic company has submitted a marketing license application. Beijing Huasu is the fourth domestic company to submit a marketing license application for this generic drug. As of the disclosure date of this announcement, the oxycodone hydrochloride sustained-release tablet project has invested a total of 17.1473 million yuan in R&D expenses.